Tectonic Therapeutic, Inc. (TECX)
| Market Cap | 418.36M +39.0% |
| Revenue (ttm) | n/a |
| Net Income | -85.79M |
| EPS | -4.56 |
| Shares Out | 19.55M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 74,495 |
| Open | 21.08 |
| Previous Close | 20.96 |
| Day's Range | 21.06 - 21.51 |
| 52-Week Range | 15.45 - 39.53 |
| Beta | 0.38 |
| Analysts | Strong Buy |
| Price Target | 71.00 (+231.78%) |
| Est. Earnings | Nov 5, 2026 |
About TECX
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company’s lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPC... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for TECX stock is "Strong Buy." The 12-month stock price target is $71.0, which is an increase of 231.78% from the latest price.
News
Tectonic Therapeutic Slides: Conference presentation
Tectonic Therapeutic has posted slides in relation to its latest quarterly earnings report, which was published on October 13, 2026.
Tectonic Therapeutic initiated with a Neutral at UBS
UBS analyst Alice Nettleton initiated coverage of Tectonic Therapeutic (TECX) with a Neutral rating and $26 price target The six-minute walk distance, which will likely be the key Phase 3…
Tectonic Therapeutic Transcript: Stifel 2026 Virtual Cardiometabolic Forum
Two clinical programs are advancing: relaxin for severe pulmonary hypertension with heart failure, and an APJ antagonist for HHT, both showing promising safety and efficacy signals. Dose selection and patient population are key differentiators, with upcoming readouts expected to clarify clinical benefit.
Tectonic Therapeutic announces results from Phase 1a trial of TX2100
Tectonic Therapeutic (TECX) announced favorable topline results from its Phase 1a clinical trial evaluating TX2100, an investigational VHH-Fc fusion antagonist antibody targeting the APJ receptor, in ...
Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
U.S. FDA has granted Fast Track designation for TX2100 in HHT and cleared the Investigational New Drug (IND) application for the TX2100 Phase 1b clinical trial in HHT patients in the U.S. TX2100 Phase...
Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference
WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeu...
Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights
Enrollment completed in TX45 APEX Phase 2 clinical trial in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-HFpEF”) with topline results antici...
Tectonic Therapeutic Quarterly report: Q2 2026
Tectonic Therapeutic has published its Q2 2026 quarterly earnings report on August 6, 2026.
Tectonic Therapeutic Earnings release: Q2 2026
Tectonic Therapeutic released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Tectonic Therapeutic Slides: Investor presentation
Tectonic Therapeutic has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Tectonic Therapeutic completes enrollment for APEX trial
Tectonic Therapeutic (TECX) announced the completion of enrollment for the APEX trial, a 24-week Phase 2 clinical trial evaluating the safety and efficacy of TX45 in patients with pulmonary hypertensi...
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients
WATERTOWN, Mass., June 10, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on the discovery and develop...
Tectonic Therapeutic Transcript: AGM 2026
The meeting covered board elections, auditor ratification, and executive compensation, with all proposals approved by shareholders. No questions were raised, and voting results will be filed with the SEC within four business days.
Tectonic Therapeutic upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst Martin Auster upgraded Tectonic Therapeutic (TECX) to Strong Buy from Outperform with a price target of $81, up from $76. The company offers an “uncommonly attractive opportunity...
Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights
WATERTOWN, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic” or the “Company”), a clinical stage biotechnology company focused on the discovery and developm...
Tectonic Therapeutic Quarterly report: Q1 2026
Tectonic Therapeutic has published its Q1 2026 quarterly earnings report on May 7, 2026.
Tectonic Therapeutic Earnings release: Q1 2026
Tectonic Therapeutic released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Tectonic Therapeutic Slides: Investor presentation
Tectonic Therapeutic has posted slides in relation to its latest quarterly earnings report, which was published on May 7, 2026.
Tectonic Therapeutic management to meet with Piper Sandler
Meeting to be held in Boston on April 29 hosted by Piper Sandler.
Tectonic Therapeutic Proxy statement: Proxy filing
Tectonic Therapeutic filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Tectonic Therapeutic Proxy statement: Proxy filing
Tectonic Therapeutic filed a proxy statement on April 24, 2026, providing details for shareholder voting and corporate governance matters.
Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors
WATERTOWN, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical-stage biotechnology company focused on the discovery and development of therapeu...
Tectonic Therapeutic initiated with a Buy at Stifel
Stifel initiated coverage of Tectonic Therapeutic (TECX) with a Buy rating and $75 price target The firm thinks the risk/reward ahead of the Phase 2 APEX data due in late…
Tectonic Therapeutic Transcript: Leerink Global Healthcare Conference 2026
Two clinical programs are advancing: TX45, a long-acting relaxin for pulmonary hypertension, is differentiated by patient selection and dosing, with Phase II results expected in late 2026 or early 2027. TX2100, an anti-angiogenic agent for HHT, shows strong preclinical efficacy and safety, with Phase I data due this year. The proprietary platform supports ongoing pipeline innovation.
Tectonic Therapeutic Transcript: TD Cowen 46th Annual Health Care Conference
The session highlighted progress on two clinical programs targeting major unmet needs in pulmonary hypertension and hereditary hemorrhagic telangiectasia, with key data readouts expected in late 2024 and 2026/2027. Competitive insights and trial design refinements position the pipeline for significant impact.